LeMaitre Vascular (NASDAQ:LMAT) Reaches New 1-Year High at $88.86

LeMaitre Vascular, Inc. (NASDAQ:LMAT)’s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $88.86 and last traded at $88.55, with a volume of 73587 shares changing hands. The stock had previously closed at $86.20.

Analysts Set New Price Targets

LMAT has been the topic of a number of research analyst reports. StockNews.com upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Wednesday, July 17th. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and increased their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Barrington Research lifted their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Roth Mkm reissued a “buy” rating and set a $100.00 price target on shares of LeMaitre Vascular in a research report on Friday, May 31st. Finally, JMP Securities lifted their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $77.57.

LeMaitre Vascular Stock Up 2.5 %

The company has a market cap of $1.98 billion, a PE ratio of 57.09, a price-to-earnings-growth ratio of 2.63 and a beta of 0.89. The firm has a 50 day simple moving average of $80.92 and a 200-day simple moving average of $69.64.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The firm had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. During the same quarter in the previous year, the firm earned $0.27 EPS. The company’s quarterly revenue was up 13.6% compared to the same quarter last year. As a group, equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 EPS for the current year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th were given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.72%. The ex-dividend date of this dividend was Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

Insider Transactions at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $75.30, for a total value of $602,400.00. Following the transaction, the chief executive officer now directly owns 2,079,128 shares of the company’s stock, valued at approximately $156,558,338.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO George W. Lemaitre sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The stock was sold at an average price of $75.30, for a total transaction of $602,400.00. Following the completion of the sale, the chief executive officer now directly owns 2,079,128 shares in the company, valued at $156,558,338.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David B. Roberts sold 5,025 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the completion of the transaction, the director now owns 14,114 shares in the company, valued at approximately $1,067,300.68. The disclosure for this sale can be found here. Insiders sold a total of 127,437 shares of company stock valued at $10,076,242 in the last three months. 10.79% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Institutional investors and hedge funds have recently bought and sold shares of the business. Quantbot Technologies LP increased its stake in shares of LeMaitre Vascular by 1,001.4% in the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after acquiring an additional 6,669 shares during the last quarter. Ranger Investment Management L.P. raised its stake in LeMaitre Vascular by 1.5% during the fourth quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after purchasing an additional 13,681 shares during the period. Congress Asset Management Co. MA grew its stake in shares of LeMaitre Vascular by 12.0% in the 1st quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock valued at $44,201,000 after buying an additional 71,411 shares during the period. Vanguard Group Inc. increased its holdings in shares of LeMaitre Vascular by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,510,567 shares of the medical instruments supplier’s stock worth $82,296,000 after buying an additional 33,500 shares during the last quarter. Finally, Mesirow Institutional Investment Management Inc. purchased a new stake in shares of LeMaitre Vascular during the 4th quarter valued at approximately $8,837,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.